Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter ended September 30, 2026, after the market close on Thursday, November 5th and will also host a conference call and webcast at 4:30 pm Eastern Time on November 5, 2026.
Arcturus Therapeutics Third Quarter 2026 Earnings Conference Call
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus’ strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes programs in cystic fibrosis (CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com
Source: Arcturus Therapeutics Holdings Inc.
Key Terms
sa-mrnamedical
sa-mRNA, or self-amplifying messenger RNA, is an engineered RNA molecule used as a vaccine or therapeutic that carries not only the code for a target protein but also viral-derived replication machinery so the RNA can make many more copies of itself inside a cell. Because it replicates inside the cell, sa-mRNA can produce higher levels of the encoded protein from a smaller initial dose than conventional (non-replicating) mRNA; it is still delivered like other mRNA therapies and triggers protein production through the cell’s translational machinery.
siRNAtechnical
Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.
circular RNAtechnical
A circular RNA is a naturally occurring molecule of genetic material shaped into a closed loop rather than a line, which makes it more stable inside cells. It can affect how genes are turned on or off and can serve as a durable marker or target for new diagnostics and therapies. Investors care because circular RNAs can create opportunities for novel drugs, more precise tests, and potentially valuable intellectual property in biotech portfolios.
antisense RNAtechnical
Short strands of RNA that are designed or occur naturally to stick to a matching messenger RNA sequence in a cell, blocking or altering the process that turns that message into a protein. For investors, antisense RNA represents a class of therapeutic technology that can create targeted medicines, influence clinical trial outcomes, affect patent and regulatory timelines, and therefore impact the value of companies developing or licensing these therapies; think of it as placing a temporary cover on a blueprint to prevent a factory from making a specific part.
ornithine transcarbamylasemedical
An enzyme in the liver cell machinery that helps convert toxic ammonia into urea for safe removal from the body, part of the urea cycle. Think of it as a specific worker on a factory line that processes a harmful raw material into a harmless product; when it is missing or defective, ammonia builds up and can cause serious illness. Its relevance to investors lies in its role as a target for diagnostic tests, drugs, and genetic therapies that can create markets or regulatory milestones in healthcare.
